Thromboprophylaxis in immobilized medical patients.
Venous thromboembolism accounts for a large number of preventable deaths. The majority of these events occur in medical patients, but medical thromboprophylaxis remains underutilised in this population. The purpose of this review is to examine the results of recent clinical trials of low molecular weight heparins in the prevention of venous thromboembolic disease in medical patients. The available data make a compelling case in favor of widespread use of low molecular weight heparin in medical patients.
Vaitkus
Paul T
PT
Cardiology, M/C 715, University of Illinois at Chicago, 840 S Wood St, Chicago, IL 60612, USA. pvaitkus@uic.edu
D000925:Anticoagulants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D007103:Immobilization / Q000009:adverse effects*; D020246:Venous Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight